These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Production of recombinant blood factors in transgenic plants. Theisen M Adv Exp Med Biol; 1999; 464():211-20. PubMed ID: 10335396 [TBL] [Abstract][Full Text] [Related]
26. Engineering mammalian cell factories for improved recombinant monoclonal antibody production: lessons from nature? Dinnis DM; James DC Biotechnol Bioeng; 2005 Jul; 91(2):180-9. PubMed ID: 15880827 [TBL] [Abstract][Full Text] [Related]
29. The rapid discovery of engineered antibodies. Wang M; He M IDrugs; 2007 Aug; 10(8):562-5. PubMed ID: 17665332 [TBL] [Abstract][Full Text] [Related]
30. Conformation-specific affinity purification of proteins using engineered binding proteins: application to the estrogen receptor. Huang J; Koide A; Nettle KW; Greene GL; Koide S Protein Expr Purif; 2006 Jun; 47(2):348-54. PubMed ID: 16325424 [TBL] [Abstract][Full Text] [Related]
31. Expression and purification of a Tuber borchii fruitbody-specific protein, TBF-1, from Escherichia coli: generation of polyclonal antibodies. Palma F; Agostini D; Cerigini E; Polidori E; Stocchi V Prep Biochem Biotechnol; 2005; 35(2):145-53. PubMed ID: 15881596 [TBL] [Abstract][Full Text] [Related]
32. [Separation strategy of affinity chromatography for mixed antibodies]. Zhou Y; Zhang Y; Luo J; Kang L; Chen Y; Shi H; Meng Q; Su Z Se Pu; 2013 Oct; 31(10):974-9. PubMed ID: 24432640 [TBL] [Abstract][Full Text] [Related]
33. Humanized antibodies as potential drugs for therapeutic use. Merluzzi S; Figini M; Colombatti A; Canevari S; Pucillo C Adv Clin Path; 2000 Apr; 4(2):77-85. PubMed ID: 11080787 [TBL] [Abstract][Full Text] [Related]
34. Laboratory production of antimicrobial peptides in native conformation. Valore EV; Ganz T Methods Mol Biol; 1997; 78():115-31. PubMed ID: 9276301 [No Abstract] [Full Text] [Related]
35. Plasma proteins. A review. Simmons P; Penny R; Goller I Med J Aust; 1969 Sep; 2(10):494-506. PubMed ID: 4186516 [No Abstract] [Full Text] [Related]
36. Performance evaluation of affinity ligands for depletion of abundant plasma proteins. Kullolli M; Warren J; Arampatzidou M; Pitteri SJ J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Nov; 939():10-6. PubMed ID: 24090752 [TBL] [Abstract][Full Text] [Related]
37. Generation and production of engineered antibodies. Kipriyanov SM; Le Gall F Mol Biotechnol; 2004 Jan; 26(1):39-60. PubMed ID: 14734823 [TBL] [Abstract][Full Text] [Related]
38. [Gene cloning and expression of human bactericidal/permeability-increasing protein]. Xu J; Xu J; Wang H Wei Sheng Wu Xue Bao; 2001 Dec; 41(6):669-73. PubMed ID: 12552821 [TBL] [Abstract][Full Text] [Related]
39. Comparison of two expression platforms in respect to protein yield and quality: Pichia pastoris versus Pichia angusta. Mack M; Wannemacher M; Hobl B; Pietschmann P; Hock B Protein Expr Purif; 2009 Aug; 66(2):165-71. PubMed ID: 19358890 [TBL] [Abstract][Full Text] [Related]
40. Purification of the human erythrocyte nucleoside transporter by immunoaffinity chromatography. Kwong FY; Davies A; Tse CM; Young JD; Henderson PJ; Baldwin SA Biochem J; 1988 Oct; 255(1):243-9. PubMed ID: 3196318 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]